Loading clinical trials...

Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms

A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Assess the Safety and Efficacy of Citalopram in Combination With Lithium or Placebo in the Treatment of Symptoms in Patients With Depressive Mood Disorders

NCT01189812•Columbia Northwest Pharmaceuticals

View on ClinicalTrials.gov

Summary

The investigators hypothesize that patients receiving citalopram in combination with lithium will have a greater reduction in depressive symptoms than patients receiving citalopram in combination with placebo.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•18-75 years of age
•Meets criteria for Major Depressive Disorder, Dysthymia, Depression Not Otherwise Specified or Borderline Personality Disorder
•Ability to speak, read and understand the English Language and provide written informed consent

Exclusion Criteria

•Current, unstable and significant medical condition or illness
•History of Thyroid disorder, seizure disorder, tumors or other CNS condition that predisposes the patient to risk of seizure
•Pregnant or lactating females
•Abnormal clinical laboratory test results
•Intolerance or hypersensitivity to SSRIs or lithium
•History or current diagnosis of bipolar mood disorder, psychosis, schizophrenia or dementia
•Certain mediations my not be used prior or during the study

Locations (2)

Artemis Institute for Clinical Research

San Diego, California, United States

Northwest Clinical Research Center

Bellevue, Washington, United States

Key Dates

Start Date

March 1, 2010

Primary Completion Date

January 1, 2011

Completion Date

January 1, 2011

Last Updated

August 24, 2011

Enrollment

ACTUAL participants

Conditions

Major Depressive DisorderDysthymiaDepression Not Otherwise SpecifiedBorderline Personality Disorder

Interventions

Lithium Carbonate

DRUG

Placebo

DRUG

Citalopram

DRUG

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

NCT07115329

Major Depressive Disorder

View study

RECRUITINGPHASE3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397

Major Depressive Disorder (MDD)Depression in Adults+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 24, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Accelerated Intermittent Theta Burst Stimulation for Adolescent and Young Adult Depression With Elevated Suicide Risk

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

University of Iowa Interventional Psychiatry Service Patient Registry

Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use